Skip to main content
PCVX logo

PCVX · Vaxcyte, Inc.

Track PCVX — free
$60.00 +1.48 (+2.53%)
Market Cap
$9.26B
Shares
158.30M
Volume · Nov 19 141.54K Avg daily vol (3M) 2.16M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$58.52 Open$59.16 Day$57.60–59.81 52W close$43.06–73.82 Avg vol 30d2.1M Short int15.4M · 9.7% of shares · 6.7d Short vol64% Last earningsOct 5, 2026 DataJun 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Feb 23, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 18
Investor event
Vax31 Adult Phase III Met All Endpoints; BLA Planned 2028

Vaxcyte said its pivotal Phase III study of VAX-31 in adults met all endpoints. It plans a BLA filing in the first half of 2028, with two more Phase III studies reading out in the first half of next year. Infant Phase II data for VAX-31 is also expected in the first half of next year.

3 source passages
we met all of the endpoints for that study, setting us up to put a BLA in place in the first half of 2028 There are two other Phase III studies that are fully enrolled that we'll read out in the first half of next year. We will be in receipt of the phase two data for Vax31 in infants, which is the other part of this market in the first half of next year Open the document at this passage
Nov 10
Investor event
Adult vaccine data exceed expectations ahead of 2028 BLA

VaxCite said its adult Vax31 Phase III data exceeded expectations, while the program remains on track for a BLA submission in the first half of 2028.

5 source passages
Look, this is a very exciting time for VaxCite. And this study is the anchor for our Phase III program of VAC Story 1 in adults to ultimately enable a BLA submission. The data exceeded our own expectations, and we're thrilled to have the profile that we see with this vaccine. We are coming off about a month away, removed from our results from our first pivotal phase three study of Vax31, our PCV, a 31-valent PCV in the adult population. The rest of the program is comprised of the Opus 2 and Opus 3 studies, for which we expect date in the first half of next year, as well as a manufacturing consistency study, all to enable a BLA submission for which we're guiding in the first half of 2028. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
VAX-31 meets pivotal Phase 3 endpoints, raising $1.15 billion

VAX-31 met all prespecified primary endpoints in the pivotal adult Phase 3 OPUS-1 trial and was well tolerated. Vaxcyte raised approximately $1.15 billion in October 2026 and held $2.3 billion of cash, cash equivalents and investments as of September 30, 2026.

Net loss $297.06M Diluted EPS -$1.99
Read from the MD&A section
4 source passages
In October 2026, we announced positive topline results from the pivotal adult Phase 3 trial of VAX-31 (“OPUS-1”). In October 2026, we announced positive results from the OPUS-1 trial. VAX-31 was well tolerated and demonstrated a safety profile similar to PCV20 and PCV21 across all ages studied. VAX-31 met all prespecified primary endpoints across age groups studied compared to PCV20 and/or PCV21. Completed $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes: In October 2026, we completed concurrent underwritten public offerings that were initiated following the disclosure of the OPUS-1 trial results. The aggregate gross proceeds to us from these offerings were approximately $1.15 billion, before deducting underwriting discounts and commissions and other offering expenses payable by us. Our net loss was $297.1 million and $902.0 million for the three and nine months, respectively, ended September 30, 2026. As of September 30, 2026, we had an accumulated deficit of $3.1 billion and cash, cash equivalents and investments of $2.3 billion. Open the document at this passage
Nov 4
Current report 8-K
VAX-31 met all OPUS-1 primary endpoints

Vaxcyte reported that VAX-31 met all prespecified primary endpoints in the OPUS-1 pivotal Phase 3 trial. Third-quarter net loss was $297.1 million, while cash, cash equivalents and investments totaled $2,264.4 million as of September 30, 2026.

Financial results
4 source passages
VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety Profile Similar to PCV20 and PCV21 Across All Ages Studied Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced financial results for the third quarter ended September 30, 2026, and provided a business update. Cash Position: Cash, cash equivalents and investments were $2,264.4 million as of September 30, 2026, compared to $2,442.6 million as of December 31, 2025. Net Loss: For the three months ended September 30, 2026, net loss was $297.1 million, compared to $212.8 million for the same period in 2025. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$1.15B
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-10.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.29B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+9.3%
Year over year · more shares
Price change (1Y)
+18.2%
Trailing year
Short interest
9.7%
Latest settlement · 6.7 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Strong Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg +1%
above
Price vs 50-day avg −6%
below
RSI (14) 42
neutral
MACD trend Negative
52-week position 50%
mid-range
Momentum
relative strength
Strong
1-month return −7%
trailing
6-month return +14%
trailing
YTD return +27%
this year
Relative strength +17%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $62 › 200d $58 — 50d above 200d
Institutional flow Accumulating
+7% holders QoQ · +65 funds added
Insider flow Distributing
Net -$376.2K over 90 days · 100% sells
Short interest Rising
9.70% of shares out · ▲ +5.0% MoM · 6.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
361 holders — near 3-yr high, broad support
Squeeze score 78
high risk · 0–100
Fundamentals
Poor
EPS growth −48%
Y/Y
Free cash flow $-669.3M
Quant / Vol
risk profile
Very High
Volatility 56%
annualized · 1-yr
Max drawdown −28%
past year
ATR 5.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 6, 2025
Capital and facility buildout expenditures (total cost) · buildout completed by early 2026 $300M – $350M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+1% Bullish
Price vs 50-day avg
−6% Bearish
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
50% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $62 › 200d $58 — 50d above 200d
Institutional flow Accumulating
+7% holders QoQ · +65 funds added
Insider flow Distributing
Net -$376.2K over 90 days · 100% sells
Short interest Rising
9.70% of shares out · ▲ +5.0% MoM · 6.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
361 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $43 Now $59 · 50% Range high $74
vs 200-day avg +1% vs 50-day avg -6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PCVX
Vaxcyte, Inc.
this stock
$9.26B +26.8% — — 9.7%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
361
% held
107.3%
Net QoQ
+2.8M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
460
View
Short & Settlement
Short Interest Rising
Shares short
15.4M
Days to cover
6.7d
Change
+736.1K sh
View
Short Volume
Short vol %
64%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
27.0K
Value
$1.6M
As of
Oct 27, 2026
View
Off-Exchange
Off-exchange %
48.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$376.2K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Congressional Trades Buy
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
Jul 16, 2026
View
Financials
Financials
Net income (FY)
$-766.6M
EPS diluted
$-5.63
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 18, 2026
This year
23

Vaxcyte said its pivotal Phase III study of VAX-31 in adults met all endpoints. It plans a BLA filing in the first half of 2028, with two more Phase III studies reading out in the first half of next year. Infant Phase II data for VAX-31 is also expected in the first half of next year.

View
Proposed Sales
Value
$1.2M
Shares
17.0K
Filed
Nov 12, 2026
View
Exempt Offerings
Offering
$110.0M
Filed
Apr 3, 2020
View
Earnings & Events
Webcasts
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Vaxcyte Reports Third Quarter 202…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
PCVX -14.7% -7.5% +13.9% -5.7% +26.8%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -10.8% -1.9% +17.3% -2.3% +19.8%
Key facts CIK 1649094 CUSIP 92243G108 13F (30d) 372 filings 338 filers Visit website Investor relations